Skip to main
MIST

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals is poised for growth with its FDA-approved drug Cardamyst for the treatment of PSVT. The company's focus on expanding into the Chinese market and conducting clinical trials for additional indications shows potential for increased revenue and market share. However, challenges in adoption and insurance coverage may affect its success in the US market.

Bears say

Milestone Pharmaceuticals is heavily dependent on its sole product, Cardamyst, and its success in the market. With limited diversification and a relatively small market size compared to its U.S. counterpart, the company's revenue growth and potential profitability could be constrained. Additionally, the success of its current and future pipeline products may be uncertain and could increase the company's financial and commercial risks. And, with a relatively high valuation and a need for continued investment to drive growth, there are concerns about potential dilution risk in the future.

MIST has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 4 analysts, MIST has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.